Annexon Presents Phase 2 ARCHER Data On Protection Of Vision And Photoreceptors With ANX007 In GA At The Retina Society 57th Annual Meeting And 24th Euretina Congress
Annexon Presents Phase 2 ARCHER Data On Protection Of Vision And Photoreceptors With ANX007 In GA At The Retina Society 57th Annual Meeting And 24th Euretina Congress
Only Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the Fovea Region Critical for Visual Acuity
唯一一個在標準和弱光條件下表現出顯著的視力保護以及在中央凹區域顯著保存光感受器的項目，這對視力至關重要
ARCHER II Phase 3 Pivotal Program in GA Underway with Data Expected Second Half 2026
喬治亞州ARCHER II第三階段關鍵項目正在進行中，預計將於2026年下半年提供數據
BRISBANE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain, and eye, today announced the Company will present analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy (GA) at the Retina Society's 57th annual scientific meeting being held September 11-15 in Lisbon, Portugal, and at the 24th annual Euretina Congress being held September 19–22 in Barcelona, Spain. ANX007 is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation.
加利福尼亞州布里斯班，2024 年 9 月 9 日（GLOBE NEWSWIRE）——推進身體、大腦和眼部神經炎症性疾病新補體療法的生物製藥公司安妮森公司（納斯達克股票代碼：ANNX）今天宣佈，該公司將在9月11日舉行的視網膜學會第 57 屆年度科學會議上介紹對已完成的地理萎縮 (GA) 二期 ARCHER 試驗 ANX007 的分析 15 在葡萄牙里斯本舉行，以及9月19日至22日在西班牙巴塞羅那舉行的第24屆年度Euretina大會上。ANX007 是首創的非聚乙二醇化抗原結合片段 (Fab)，旨在使用玻璃體注射製劑阻斷眼部局部 C1q。
譯文內容由第三人軟體翻譯。
